vs
Jaguar Health, Inc.（JAGX）与Rigetti Computing, Inc.（RGTI）财务数据对比。点击上方公司名可切换其他公司
Jaguar Health, Inc.的季度营收约是Rigetti Computing, Inc.的1.7倍（$3.2M vs $1.9M），Jaguar Health, Inc.净利率更高（-717.2% vs -974.7%，领先257.5%），Jaguar Health, Inc.同比增速更快（-7.8% vs -17.9%），过去两年Jaguar Health, Inc.的营收复合增速更高（17.3% vs -21.8%）
Jaguar Health, Inc.是一家处于商业化阶段的生物制药企业，专注于开发和商业化植物源处方药物，覆盖人用和动物用两大领域，核心管线针对胃肠道领域未被满足的医疗需求，主要市场覆盖北美及部分欧洲区域。
Rigetti Computing总部位于美国加利福尼亚州伯克利，是专业的超导量子集成电路研发商，产品主要应用于量子计算机领域。公司还推出了名为Forest的云平台，支持开发者编写各类量子算法。
JAGX vs RGTI — 直观对比
营收规模更大
JAGX
是对方的1.7倍
$1.9M
营收增速更快
JAGX
高出10.0%
-17.9%
净利率更高
JAGX
高出257.5%
-974.7%
两年增速更快
JAGX
近两年复合增速
-21.8%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $3.2M | $1.9M |
| 净利润 | $-23.2M | $-18.2M |
| 毛利率 | 32.0% | 34.9% |
| 营业利润率 | -656.6% | -1209.7% |
| 净利率 | -717.2% | -974.7% |
| 营收同比 | -7.8% | -17.9% |
| 净利润同比 | -133.9% | 88.1% |
| 每股收益（稀释后） | $10.27 | $-0.08 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收JAGXRGTI
| Q4 25 | $3.2M | $1.9M | ||
| Q3 25 | $3.1M | $1.9M | ||
| Q2 25 | $3.0M | $1.8M | ||
| Q1 25 | $2.2M | $1.5M | ||
| Q4 24 | $3.5M | $2.3M | ||
| Q3 24 | $3.1M | $2.4M | ||
| Q2 24 | $2.7M | $3.1M | ||
| Q1 24 | $2.4M | $3.1M |
净利润JAGXRGTI
| Q4 25 | $-23.2M | $-18.2M | ||
| Q3 25 | $-9.5M | $-201.0M | ||
| Q2 25 | $-10.4M | $-39.7M | ||
| Q1 25 | $-10.5M | $42.6M | ||
| Q4 24 | $-9.9M | $-153.0M | ||
| Q3 24 | $-9.9M | $-14.8M | ||
| Q2 24 | $-9.5M | $-12.4M | ||
| Q1 24 | $-9.2M | $-20.8M |
毛利率JAGXRGTI
| Q4 25 | 32.0% | 34.9% | ||
| Q3 25 | 82.7% | 20.7% | ||
| Q2 25 | 82.3% | 31.4% | ||
| Q1 25 | 76.7% | 30.0% | ||
| Q4 24 | 84.1% | 44.1% | ||
| Q3 24 | 82.6% | 50.6% | ||
| Q2 24 | 84.3% | 64.5% | ||
| Q1 24 | 81.7% | 49.1% |
营业利润率JAGXRGTI
| Q4 25 | -656.6% | -1209.7% | ||
| Q3 25 | -234.8% | -1055.4% | ||
| Q2 25 | -268.8% | -1103.9% | ||
| Q1 25 | -425.5% | -1469.6% | ||
| Q4 24 | -232.5% | -813.3% | ||
| Q3 24 | -233.7% | -729.4% | ||
| Q2 24 | -264.5% | -521.2% | ||
| Q1 24 | -349.4% | -543.4% |
净利率JAGXRGTI
| Q4 25 | -717.2% | -974.7% | ||
| Q3 25 | -308.2% | -10321.9% | ||
| Q2 25 | -349.3% | -2201.8% | ||
| Q1 25 | -472.6% | 2895.3% | ||
| Q4 24 | -282.7% | -6726.5% | ||
| Q3 24 | -317.1% | -623.8% | ||
| Q2 24 | -348.8% | -402.5% | ||
| Q1 24 | -392.4% | -680.6% |
每股收益（稀释后）JAGXRGTI
| Q4 25 | $10.27 | $-0.08 | ||
| Q3 25 | $-6.28 | $-0.62 | ||
| Q2 25 | $-10.26 | $-0.13 | ||
| Q1 25 | $-16.70 | $0.13 | ||
| Q4 24 | $-14.62 | $-0.80 | ||
| Q3 24 | $-1.05 | $-0.08 | ||
| Q2 24 | $-4.04 | $-0.07 | ||
| Q1 24 | $-0.06 | $-0.14 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $968.0K | $44.9M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $-18.7M | $546.2M |
| 总资产 | $38.3M | $666.6M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资JAGXRGTI
| Q4 25 | $968.0K | $44.9M | ||
| Q3 25 | $3.5M | $26.1M | ||
| Q2 25 | $2.2M | $57.2M | ||
| Q1 25 | $5.7M | $37.2M | ||
| Q4 24 | $8.0M | $67.7M | ||
| Q3 24 | $13.3M | $20.3M | ||
| Q2 24 | $16.0M | $20.7M | ||
| Q1 24 | $11.7M | $35.1M |
股东权益JAGXRGTI
| Q4 25 | $-18.7M | $546.2M | ||
| Q3 25 | $4.4M | $371.8M | ||
| Q2 25 | $6.9M | $553.3M | ||
| Q1 25 | $830.0K | $207.1M | ||
| Q4 24 | $6.5M | $126.6M | ||
| Q3 24 | $13.1M | $122.8M | ||
| Q2 24 | $16.6M | $122.2M | ||
| Q1 24 | $11.8M | $115.6M |
总资产JAGXRGTI
| Q4 25 | $38.3M | $666.6M | ||
| Q3 25 | $49.5M | $630.3M | ||
| Q2 25 | $48.3M | $636.7M | ||
| Q1 25 | $51.5M | $269.1M | ||
| Q4 24 | $53.4M | $284.8M | ||
| Q3 24 | $58.5M | $157.3M | ||
| Q2 24 | $61.5M | $162.4M | ||
| Q1 24 | $55.4M | $162.1M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-5.5M | $-14.9M |
| 自由现金流经营现金流 - 资本支出 | — | $-19.5M |
| 自由现金流率自由现金流/营收 | — | -1042.5% |
| 资本支出强度资本支出/营收 | — | 244.8% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $-77.2M |
8季度趋势，按日历期对齐
经营现金流JAGXRGTI
| Q4 25 | $-5.5M | $-14.9M | ||
| Q3 25 | — | $-13.8M | ||
| Q2 25 | — | $-16.2M | ||
| Q1 25 | $-7.3M | $-13.7M | ||
| Q4 24 | $-7.8M | $-8.5M | ||
| Q3 24 | — | $-15.4M | ||
| Q2 24 | — | $-13.5M | ||
| Q1 24 | $-7.0M | $-13.1M |
自由现金流JAGXRGTI
| Q4 25 | — | $-19.5M | ||
| Q3 25 | — | $-19.7M | ||
| Q2 25 | — | $-21.8M | ||
| Q1 25 | — | $-16.2M | ||
| Q4 24 | — | $-9.8M | ||
| Q3 24 | — | $-17.7M | ||
| Q2 24 | — | $-15.6M | ||
| Q1 24 | — | $-18.6M |
自由现金流率JAGXRGTI
| Q4 25 | — | -1042.5% | ||
| Q3 25 | — | -1012.4% | ||
| Q2 25 | — | -1212.4% | ||
| Q1 25 | — | -1100.4% | ||
| Q4 24 | — | -432.1% | ||
| Q3 24 | — | -744.5% | ||
| Q2 24 | — | -504.3% | ||
| Q1 24 | — | -610.5% |
资本支出强度JAGXRGTI
| Q4 25 | — | 244.8% | ||
| Q3 25 | — | 302.5% | ||
| Q2 25 | — | 314.7% | ||
| Q1 25 | — | 173.0% | ||
| Q4 24 | — | 56.4% | ||
| Q3 24 | — | 95.8% | ||
| Q2 24 | — | 66.3% | ||
| Q1 24 | — | 180.0% |
现金转化率JAGXRGTI
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | -0.32× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
JAGX
| Human Health Segment | $3.2M | 97% |
| Other | $83.0K | 3% |
RGTI
| Collaborative Research And Other Professional Services | $1.7M | 93% |
| Other | $131.0K | 7% |
